Morgan Stanley raised the firm’s price target on Legend Biotech (LEGN) to $81 from $80 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Positive Growth Outlook for Legend Biotech Driven by Carvykti Sales and Strategic Expansion
- Strong Buy Rating for Legend Biotech’s CARVYKTI Amid Limited Competition and Favorable Risk Profile
- Legend Biotech price target lowered to $54 from $60 at UBS
- Promising Outlook for Legend Biotech’s CARVYKTI: Buy Rating Affirmed by Mitchell Kapoor
- Legend Biotech’s CAR T Cell Therapies See FDA REMS Removal and EMA Label Update